Legend Biotech (LEGN) Accounts Payables (2019 - 2025)

Legend Biotech's Accounts Payables history runs 7 years deep, the most recent figure standing at $83.0 million for Q4 2025.

• Quarterly Accounts Payables rose 115.03% year-over-year to $83.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $83.0 million (up 115.03% YoY) and the FY2025 annual result came in at $83.0 million, up 115.03% from the prior year.
• Accounts Payables was $83.0 million for Q4 2025 at Legend Biotech, down from $102.5 million in the prior quarter.
• Across five years, Accounts Payables topped out at $102.5 million in Q3 2025 and bottomed at $7.0 million in Q4 2021.
• A 5-year average of $40.8 million and a median of $32.9 million in 2022 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables soared 367.03% — and 2023, when it dropped 6.8%.
• Legend Biotech's Accounts Payables stood at $7.0 million in 2021, then surged by 367.03% to $32.9 million in 2022, then slipped by 6.8% to $30.7 million in 2023, then grew by 25.92% to $38.6 million in 2024, then surged by 115.03% to $83.0 million in 2025.
• Business Quant data shows LEGN's Accounts Payables at $83.0 million in Q4 2025, $102.5 million in Q3 2025, and $75.4 million in Q2 2025.